Literature DB >> 6257877

Prevention of transfusion-acquired cytomegalovirus infections in newborn infants.

A S Yeager, F C Grumet, E B Hafleigh, A M Arvin, J S Bradley, C G Prober.   

Abstract

Transfusion-acquired cytomegalovirus infections occurred in 13.5% of 74 infants of seronegative mothers who were exposed to one or more blood donors who had a CMV indirect hemagglutination titer of 1:8 or higher. None of 90 infants of seronegative mothers exposed only to donors with CMV IHA titers of less than 1:8 became infected. Ten of 41 (24%) infants of seronegative mothers who received more than 50 ml of packed red blood cells and who were exposed to at least one seropositive donor became infected. None of 23 infants of seronegative mothers who received this amount of blood but who were exposed only to seronegative donors became infected. Fatal or serious symptoms developed in 50% of the infected infants of seronegative mothers and in none of the 32 infected infants of seropositive mothers. Acquired CMV infections occurred in 15% of infants of seropositive mothers who were exposed to the red blood cells of seropositive donors and in 17.6% of infants of seropositive mothers exposed only to seronegative donors. Use of seronegative donors reduced the prevalence of excretion of CMV among hospitalized infants who were 4 weeks of age or older from 12.5 to 1.8% and eliminated acquired CMV infections in infants of seronegative mothers.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6257877     DOI: 10.1016/s0022-3476(81)80662-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  77 in total

Review 1.  Cytomegalovirus transmission from breast milk in premature babies: does it matter?

Authors:  P Bryant; C Morley; S Garland; N Curtis
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-09       Impact factor: 5.747

Review 2.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

3.  Early acquisition of cytomegalovirus infection.

Authors:  C S Peckham; C Johnson; A Ades; K Pearl; K S Chin
Journal:  Arch Dis Child       Date:  1987-08       Impact factor: 3.791

4.  Seroprevalence of cytomegalovirus among some voluntary blood donors at the 37 military hospital, accra, ghana.

Authors:  Aa Adjei; Hb Armah; Eg Narter-Olaga
Journal:  Ghana Med J       Date:  2006-09

5.  Fatal congenital cytomegalovirus infection acquired by an intra-uterine transfusion.

Authors:  D G Evans; A J Lyon
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

Review 6.  Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?

Authors:  Malte Ziemann; Holger Hennig
Journal:  Transfus Med Hemother       Date:  2013-12-19       Impact factor: 3.747

7.  Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites.

Authors:  J A Simpson; J C Chow; J Baker; N Avdalovic; S Yuan; D Au; M S Co; M Vasquez; W J Britt; K L Coelingh
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.

Authors:  Frances M Saccoccio; Anne L Sauer; Xiaohong Cui; Amy E Armstrong; El-Sayed E Habib; David C Johnson; Brent J Ryckman; Aloysius J Klingelhutz; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

9.  Pulmonary disease following allogeneic bone marrow transplantation.

Authors:  M Murray; D S O'Briain; J Prichard; S R McCann
Journal:  Ir J Med Sci       Date:  1989-02       Impact factor: 1.568

10.  Transfusion-related cytomegalovirus infection among very low birth weight infants in an endemic area.

Authors:  Ai-Rhan Ellen Kim; Yeon Kyung Lee; Kyung Ah Kim; Young Kyu Chu; Byung Yoon Baik; Eun Soon Kim; Sung Cheol Yun; Ki Soo Kim; Soo Young Pi
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.